RIGImmune

RIGImmune is a private, preclinical-stage biotech founded in 2020 by Yale professors Anna Marie Pyle and Akiko Iwasaki. The company has built an integrated platform combining Stem Loop RNA (SLR) therapeutics, which selectively activate the RIG-I pathway, with the NEED™ (Nano-Emulsion Enhanced Delivery) platform for direct, non-LNP inhalation delivery. Its pipeline targets high-unmet-need respiratory conditions like asthma and cystic fibrosis, positioning it to address a significant market opportunity if its localized delivery approach proves successful in the clinic.

NEED™ (Nano-Emulsion Enhanced Delivery) platform for non-LNP, inhaled delivery of RNA therapeutics, combined with proprietary Stem Loop RNA (SLR) compounds that selectively activate the RIG-I immune pathway.

RIGImmune competes in the growing fields of inhaled biologics and RNA therapeutics for respiratory disease. Competitors include companies developing inhaled antibodies, antisense oligonucleotides, and mRNA, often using lipid or polymer-based delivery systems. Its differentiation lies in the specific RIG-I targeting and its non-LNP NEED™ emulsion platform.